* Aquestive Therapeutics Inc reported a quarterly adjusted loss of 13 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -3 cents. The mean expectation of eight analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -14 cents to -9 cents per share.

* Revenue rose 18.7% to $13.54 million from a year ago; analysts expected $12.68 million.

* Aquestive Therapeutics Inc's reported EPS for the quarter was a loss of 13 cents​.

* The company reported a quarterly loss of $11.51 million.

* Aquestive Therapeutics Inc shares had risen by 3.4% this quarter and gained 155.0% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 0.5% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Aquestive Therapeutics Inc is $9.50 This summary was machine generated from LSEG data November 5 at 07:54 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.13 -0.13 Met

Jun. 30 2024 -0.12 -0.03 Beat

Mar. 31 2024 -0.08 -0.17 Missed

Dec. 31 2023 -0.08 -0.11 Missed